

2022 Pivotal Points, Currents, and Controversies in nr-axSpA: What You May Have Missed

Links to Supporting References

Directions: Click on references to view articles and abstracts.

Braun J, Blanco R, Marzo-Ortega H, et al. Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a phase III randomized trial [abstract 0921]. *Arthritis Rheumatol.* 2021;73(Suppl 9):0921.

Deodhar A, Poddubnyy D, Blanco R, et al. Efficacy of secukinumab in patients with non-radiographic axial spondyloarthritis: analysis by symptom duration and age. Presented at: EULAR Congress 2022; June 1-4, 2022; Copenhagen, Denmark. Abstract AB0759.

Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2022;400:369-379.

Deodhar A, van der Heijde D, Gensler LS, et al. POS0939 Bimekizumab in patients with active non-radiographic axial spondyloarthritis: 24-week efficacy and safety from BE MOBILE 2, a phase 3, multicentre, randomised, placebo-controlled study. *Ann Rheum Dis.* 2022;81:772-773.

Deodhar A, van der Heijde D, Gensler L, et al. Bimekizumab improves signs and symptoms, including inflammation, in patients with active non-radiographic axial spondyloarthritis: 24-week efficacy & safety from a phase 3, multicenter, randomized, placebo controlled study [oral presentation; abstract 0544]. *Arthritis Rheumatol.* 2022;74(Suppl 9):0544.

Dubreuil M, Gaffney K, Gensler L, et al. Bimekizumab improves physical function and health-related quality of life in patients with axial spondyloarthritis: results from two phase 3 Studies [abstract 0412]. *Arthritis Rheumatol.* 2022;74(Suppl 9):0412.

Lambert R, Baraliakos X, Bernard S, et al. Development of international consensus on a standardized image acquisition protocol for diagnostic evaluation of the sacroiliac joints by MRI – an ASAS-SPARTAN Collaboration [abstract 1258]. *Arthritis Rheumatol.* 2022;74(Suppl 9):1258.

Maksymowych WP, Lambert RG, Baraliakos X, et al. Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. *Rheumatology*. 2021;60:4778-4789.

Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *Ann Rheum Dis*. 2022 Oct 21. [Online ahead of print]

Robinson PC, Maksymowych WP, Gensler LS, et al. Certolizumab pegol efficacy in patients with non-radiographic axial spondyloarthritis stratified by baseline MRI and C-reactive protein status: an analysis from the C-axSpAnd study. *ACR Open Rheumatol*. 2022;9:794-801.

Robinson P, Maksymowych W, Gensler L, et al. Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and C-reactive protein status [abstract 0408]. *Arthritis Rheumatol*. 2022;74(Suppl 9):0408.

Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*. 2009;68:770-776.

van der Heijde D, Gensler LS, Maksymowych WP, et al. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. *RMD Open*. 2022;8:e002138.

Walsh JA, Magrey MN, Baraliakos X, et al. Improvement of functioning and health with ixekizumab in the treatment of active nonradiographic axial spondyloarthritis in a 52-week, randomized, controlled trial. *Arthritis Care Res (Hoboken)*. 2022;74:451-460.